UniQure, Syndax, Erasca Drawing Fresh Analyst Interest
Three clinical-stage biotechs—UniQure, Syndax, and Erasca—are catching analyst attention ahead of key catalysts, with...
Discover why the divisor method is favored for benchmarks, offering continuity, fairness, and easier comparison across periods and actions.
21,921 articlesThree clinical-stage biotechs—UniQure, Syndax, and Erasca—are catching analyst attention ahead of key catalysts, with...
Applied Optoelectronics and Lumentum jumped about 15% on Monday as a major hyperscale contract and index-driven buyin...
Ferrari's latest results underscore its asset-like status, delivering strong cash flow while preparing for an electri...
Howmet Aerospace and GE Vernova push higher in 2026 as AI data centers and power upgrades drive engine and turbine or...
Beijing maintains tight control over rare earth processing, forcing investors and policymakers to rethink diversifica...
An ETF-based approach blends residential and mortgage REITs to generate passive income without property management. A...
When a k-pop star left group, it isn’t just a headline. It sets off a wave of spending, policy shifts, and career rei...
Rising tensions around Iran push energy costs higher and complicate the macro outlook. Analysts warn that stagflation...
G-III Apparel faces a pivotal year in 2026 as licensing momentum and margin discipline collide with shifting consumer...